Abstract
This chapter provides an overview of policy and regulatory issues relating to the use of neuropharmaceuticals for cognitive enhancement in normal persons without a cognitive disorder. It draws on experience with a range of policy and regulatory approaches to alcohol, tobacco, pharmaceutical drugs, and illicit drugs and focuses on approaches that target rates of drug use in the population as a whole. The focus on regulatory interventions for the control of neuropharmaceuticals is important because a range of pharmaceutical drugs is often reportedly used and advocated for enhancement purposes. We also examine how more public health interventions such as awareness raising, education, and stigmatization could be used as preventive strategies to reduce the use, and harm associated with the use, of neuropharmaceuticals for cognitive enhancement.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Academy of Medical Sciences. (2008). Brain science, addiction and drugs. London: United Kingdom Academy of Medical Sciences.
Australian Press Council. (2001). Guideline: Drugs and drug addiction, http://www.presscouncil.org.au/document-search/guideline-drugs-and-drug-addiction/?LocatorGroupID=662&LocatorFormID=677&FromSearch=1. Advisory Guidelines. Accessed 5 Nov 2012.
Babor, T., Caulkins, J., Edwards, G., Fischer, B., Foxcroft, D., Humphreys, K., & Strang, J. (2010). Drug policy and the public good. Oxford: Oxford University Press.
Bell, S. K., Lucke, J. C., & Hall, W. D. (2012). Lessons for enhancement from the history of cocaine and amphetamine use. AJOB Neuroscience, 3(2), 24–29.
Bostrom, N., & Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15(3), 311–341.
British Medical Association. (2007). Boosting your brainpower: Ethical aspects of cognitive enhancements. London: BMA.
Carroll, B. C., McLaughlin, T. J., & Blake, D. R. (2006). Patterns and knowledge of nonmedical use of stimulants among college students. Archives of Pediatrics & Adolescent Medicine, 160(5), 481–485.
DeSantis, A., Webb, E. M., & Noar, S. M. (2008). Illicit use of prescription ADHD medications on a college campus: A multimethodological approach. Journal of American College Health, 57(3), 315–324.
Dubljevic, V. (2012). Toward a legitimate public policy on cognition-enhancement drugs. AJOB Neuroscience, 3(3), 29–33.
Fischer, B., Bibby, M., & Bouchard, M. (2010). The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction, 105(12), 2062–2070.
Forlini, C., & Racine, E. (2009). Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders. Neuroethics, 2(3), 163–177.
Forlini, C., & Racine, E. (2012). Added stakeholders, added value(s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders? AJOB Primary Research, 3(1), 33–47.
Forlini, C., Gauthier, S., & Racine, E. (2013). Should physicians prescribe cognitive enhancers to healthy individuals? Canadian Medical Association Journal. Online ahead of print: 10.1503/cmaj.121508.
Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., & Lieb, K. (2011). Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44(2), 60–66.
Fraser, S., & Moore, D. (2011). Governing through problems: The formulation of policy on amphetamine-type stimulants (ATS) in Australia. The International Journal on Drug Policy, 22(6), 498–506.
Government of Quebec. (2009). Psychotropic drugs and expanded uses: An ethical perspective (Position Statement) Quebec: Commission de l’éthique, de la science et de la technologie.
Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223), 702–705.
Hall, W. (2004). Feeling ‘better than well:’ Can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports, 5(12), 1105–1109.
Holmes, D. (2012). Prescription drug addiction: The treatment challenge. Lancet, 379(9810), 17–18.
Hughes, B., & Winstock, A. R. (2012). Controlling new drugs under marketing regulations. Addiction, 107(11), 1894–1899.
Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., & Penne, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence, 84(2), 135–143.
Larriviere, D., Williams, M. A., Rizzo, M., & Bonnie, R. J. (2009). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology, 73(17), 1406–1412.
Lucke, J. C., Bell, S., Partridge, B., & Hall, W. D. (2011). Deflating the neuroenhancement bubble. AJOB Neuroscience, 2(4), 38–43.
Lynch, G., Palmer, L. C., & Gall, C. M. (2011). The likelihood of cognitive enhancement. Pharmacology, Biochemistry, and Behavior, 99(2), 116–129.
McCabe, S. E. (2008). Misperceptions of non-medical prescription drug use: A web survey of college students. Addictive Behaviors, 33(5), 713–724.
Nielsen, S., & Barratt, M. J. (2009). Prescription drug misuse: Is technology friend or foe? Drug and Alcohol Review, 28(1), 81–86.
Orizio, G., Merla, A., Schulz, P. J., & Gelatti, U. (2011). Quality of online pharmacies and websites selling prescription drugs: A systematic review. Journal of Medical Internet Research, 13(3), e74.
Outram, S. M., & Racine, E. (2011a). Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics, 4(1), 93–105.
Outram, S. M., & Racine, E. (2011b). Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations. Accountability in Research, 18(5), 323–341.
Partridge, B. J., Bell, S. K., Lucke, J. C., Yeates, S., & Hall, W. D. (2011). Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS One, 6(11), e28416.
Racine, E. (2008). Interdisciplinary approaches for a pragmatic neuroethics. The American Journal of Bioethics, 8(1), 52–53.
Racine, E. (2010). Pragmatic neuroethics: Improving treatment and understanding of the mind-brain. Cambridge, MA: The MIT Press.
Racine, E., & Forlini, C. (2009). Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 35(8), 469–470.
Racine, E., & Forlini, C. (2010). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. [Letter]. Neurology, 74(19), 1555–1556.
Repantis, D., Schlattmann, P., Lainsey, O., & Heuser, I. (2008). Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis Prax, 6, 139–174.
Repantis, D., Laisney, O., & Heuser, I. (2010a). Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 61(6), 473–481.
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010b). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187–206.
Roche, A. M., Bywood, P., Pidd, K., Freeman, T., & Steenson, T. (2009). Drug testing in Australian schools: Policy implications and considerations of punitive, deterrence and/or prevention measures. The International Journal on Drug Policy, 20(6), 521–528.
Room, R., & Hall, W. (2012). Population approaches to alcohol, tobacco and drugs: Effectiveness, ethics and interplay with addiction neuroscience. In A. Carter, W. D. Hall, & J. Illes (Eds.), Addiction neuroethics (pp. 247–260). London: Academic Press.
Rosenfield, D., Hebert, P. C., Stanbrook, M. B., Flegel, K., & MacDonald, N. E. (2011). Time to address stimulant abuse on our campuses. [Editorial]. Canadian Medical Association Journal, 183(12), 1345.
Sandberg, A., & Savulescu, J. (2011). The social and economic impacts of cognitive enhancement. In J. Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing human capacities. Oxford, UK: Blackwell.
Savulescu, J., & Bostrom, N. (Eds.). (2009). Human enhancement. Oxford: Oxford University Press.
Smith, M. E., & Farah, M. J. (2011). Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin, 137(5), 717–741. 717.
Stone, A. M., & Merlo, L. J. (2011). Attitudes of college students toward mental illness stigma and the misuse of psychiatric medications. The Journal of Clinical Psychiatry, 72(2), 134–139.
Strang, J., Babor, T., Caulkins, J., Fischer, B., Foxcroft, D., & Humphreys, K. (2012). Drug policy and the public good: Evidence for effective interventions. The Lancet, 379(9810), 71–83.
Swanson, J. M., Wigal, T. L., & Volkow, N. D. (2011). Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: Comment on Smith and Farah. [Comment]. Psychological Bulletin, 137(5), 742–748.
Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26(10), 1501–1510.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Lucke, J., Partridge, B., Forlini, C., Racine, E. (2015). Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues. In: Clausen, J., Levy, N. (eds) Handbook of Neuroethics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4707-4_72
Download citation
DOI: https://doi.org/10.1007/978-94-007-4707-4_72
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4706-7
Online ISBN: 978-94-007-4707-4
eBook Packages: Humanities, Social Sciences and Law